Navigation Links
BUSM professor awarded $13.3 million to study potential treatments to prevent STDs
Date:8/12/2011

(Boston) Deborah Anderson, PhD, professor of obstetrics and gynecology and microbiology at Boston University School of Medicine (BUSM) is co-leading a new study funded by a five-year $13.3 million grant from the National Institute of Allergy and Infectious Diseases (NIAID). Anderson will investigate the vaginal use of human monoclonal antibodies manufactured transiently in tobacco plants (called "plantibodies") to prevent sexually transmitted infections caused by Herpes Simplex Virus (HSV) and the Human Immunodeficiency Virus (HIV).

The production of human monoclonal antibodies and other proteins in plants is intended to provide a low-cost and large-capacity manufacturing system that could ensure an affordable supply of antibodies, vaccines and other biopharmaceuticals for at-risk populations throughout the world, including developing countries.

The research team will develop ring, film and barrier formulations to deliver the antibodies and conduct preclinical testing in vitro and in vivo using animal models to evaluate safety and antimicrobial (HSV, HIV) efficacy. The plantibodies will be tested for safety and duration of activity in a human pre-phase I clinical trial as a first step towards their use as vaginal microbicides to prevent HSV and HIV infections in women.

"We hope that this research will lead to novel ways of preventing sexually transmitted diseases, which are epidemic in the US and worldwide and have far reaching health, social and economic consequences," said Anderson. "In addition, we will be breaking ground for the potential use of plantibodies to prevent other diseases caused by pathogens that cross mucosal membranes, such as rhinoviruses (common cold) and influenza (flu), as well as dangerous emerging pathogens like the Ebola virus (hemorrhagic fever)."

The grant was awarded through the NIAID-funded Integrated Preclinical/Clinical Program for HIV Topical Microbicides. Kevin Whaley, PhD, at Mapp Biopharmaceuticals in San Diego and Thomas Moench, MD, at ReProtect Inc. in Baltimore, are the main collaborators on this research study.

The research will be conducted by a consortium of investigators at Boston University Medical Campus, University of North Carolina, Johns Hopkins University, Brown University, Emory University, Fenway Community Health, ReProtect LLC, Kentucky BioProcessing LLC, Auritec Pharmaceuticals Inc., Aridis Pharmaceuticals and Mapp Biopharmaceutical Inc.


'/>"/>

Contact: Jenny Eriksen Leary
jenny.eriksen@bmc.org
617-638-6841
Boston University Medical Center
Source:Eurekalert

Related biology news :

1. National Science Foundation grants Clemson professors award to develop nanoprobes
2. University professor stresses links between US Navy sonar and whale strandings
3. Minnesota ecology professor wins international award for biodiversity and biofuels research
4. NJIT professors research suggests changes in underwater data communications
5. 2 Alexander von Humboldt professorships go to LMU Munich
6. Top biophysics award to Professor Ray Norton
7. University of Leicester professor adds new perspective to rainforest debate
8. NJIT professor finds engineering technique to identify disease-causing genes
9. Chemistry professor 1 of only 3 at UH to achieve prestigious AAAS status
10. Florida professor creates endowment for insect scientists
11. Dinner, lecture series to honor legacy of distinguished UH professor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
(Date:3/21/2016)... Unique technology combines v ... security   Xura, Inc. ... digital communications services, today announced it is working alongside ... customers, particularly those in the Financial Services Sector, the ... within a mobile app, alongside, and in combination with, ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
Breaking Biology Technology: